Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyadic International
(NQ:
DYAI
)
1.370
-0.010 (-0.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dyadic International
< Previous
1
2
3
4
Next >
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
July 27, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 12, 2021
- Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies,...
From
Dyadic International, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Supply Chain
Exposures
COVID-19
Legal
Regulatory
Dyadic to Report Second Quarter 2021 Financial Results
July 29, 2021
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,...
From
Dyadic International, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Dyadic to Present at Upcoming Events
May 24, 2021
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its...
From
Dyadic International, Inc.
Via
AccessWire
Exposures
COVID-19
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
May 13, 2021
- Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial - Goal of validating that C1 produced proteins are safe in humans and to...
From
Dyadic International, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Dyadic to Report First Quarter 2021 Financial Results
April 29, 2021
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,...
From
Dyadic International, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.